UPDATE 1-AbbVie to buy Stemcentrx to boost cancer drug portfolio

April 28 (Reuters) - AbbVie Inc said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion to expand its portfolio of drugs to treat cancer.